Antibe Therapeutics Inc. — Form D
Antibe Therapeutics Inc. of TORONTO, A6, a company, filed a Form D exempt-offering notice with the SEC on 2019-08-29. The offering totals $4.3M, of which $283K was reported sold. Industry: Biotechnology.
Offering
- Filed: 2019-08-29
- Form: D
- Accession: 0001583682-19-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $4.3M
- Amount sold: $283K
- Remaining: $4.1M
- Investors: 1
- Date of first sale: 2019-08-13
- Security types: equity
- Revenue range: $5,000,001 - $25,000,000
- SEC file number: 021-347707
Issuer
- Name: Antibe Therapeutics Inc.
- CIK: 0001583682
- Entity type: Corporation
- Jurisdiction: ONTARIO, CANADA
- Incorporated: 2009
- Address: 15 PRINCE ARTHUR AVENUE, TORONTO, A6, M5R 1B2
- Phone: 905-570-5103
Officers, directors & promoters (12)
| Name | Role | Location |
|---|
| RODERICK FLOWER | Director | TORONTO, A6 |
| AMAL KHOURI | Director | TORONTO, A6 |
| DANIEL LEGAULT | Director | TORONTO, A6 |
| WALT MACNEE | Director | TORONTO, A6 |
| JOHN WALLACE | Director | TORONTO, A6 |
| YUNG WU | Director | TORONTO, A6 |
| DANIEL LEGAULT | Executive Officer | TORONTO, A6 |
| Alain Wilson | Executive Officer | Montreal, A8 |
| Jonathan Goodman | Director | Arlington, VA |
| David Vaughan | Executive Officer | JUPITER, FL |
| JOHN WALLACE | Executive Officer | TORONTO, A6 |
| Michael Bumby | Executive Officer | Toronto, A6 |
Other filings by this issuer (1)
More